

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| | | | |
|---|-----------------------------------|----------------|-------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | RELEASE BY SECURED PARTY | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| MidCap Funding III, LLC | | 02/08/2013 | LIMITED LIABILITY COMPANY: DELAWARE |
| RECEIVING PARTY DATA | | | |
| Name: | CeNeRx BioPharma, Inc. | | |
| Street Address: | 270 Cornerstone Drive Suite 103 | | |
| City: | Cary | | |
| State/Country: | NORTH CAROLINA | | |
| Postal Code: | 27519 | | |
| Entity Type: | CORPORATION: DELAWARE | | |
| PROPERTY NUMBERS Total: 3 | | | |
| Property Type | Number | Word Mark | |
| Registration Number: | 3662094 | CENERX | |
| Registration Number: | 3687175 | TRIRIMA | |
| Serial Number: | 77807249 | AYRENE | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Phone: | 919-781-4000 | | |
| Email: | lblackwell@wyrick.com | | |
| Correspondent Name: | Linda Blackwell | | |
| Address Line 1: | 4101 Lake Boone Trail Suite 300 | | |
| Address Line 2: | Wyrick Robbins Yates & Ponton LLP | | |
| Address Line 4: | Raleigh, NORTH CAROLINA 27607 | | |
| ATTORNEY DOCKET NUMBER: | 20515.1 LFB (765055) | | |

OP \$90.00 3662094

| | |
|---|-----------------------------------|
| NAME OF SUBMITTER: | Robert Goodridge, General Counsel |
| Signature: | /Robert Goodridge/ |
| Date: | 03/19/2013 |
| Total Attachments: 6 source=MidCap Funding III, LLC Release 2#page1.tif source=MidCap Funding III, LLC Release 2#page2.tif source=MidCap Funding III, LLC Release 2#page3.tif source=MidCap Funding III, LLC Release 2#page4.tif source=MidCap Funding III, LLC Release 2#page5.tif source=MidCap Funding III, LLC Release 2#page6.tif | |

RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

THIS RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST made and entered effective as of February 8, 2013, by the below signatory hereto (the "Lender"), in favor of CeNeRx BioPharma, Inc., a Delaware corporation, (the "Borrower").

WHEREAS, Lender and Borrower were parties to a certain Intellectual Property Security Agreement dated as of November 22, 2010 (the "Security Agreement") and recorded in the United States Patent and Trademark Office on January 10, 2011 at Reel 025764/ Frame 0546, under which Borrower granted Lender a security interest in Borrower's trademarks and patents, including but not limited to the trademarks and patents listed on Schedule A hereto; and

WHEREAS, Lender now desires to release and terminate any security interest it may have as to the trademarks and patents listed on Schedule A (the "Security Interest").

NOW THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Lender hereby terminates the Security Interest and releases to Borrower all interest which Lenders possess or are otherwise entitled to in the patents and trademarks listed on Schedule A hereto by virtue of such Security Agreement.

[Signature page follows.]

IN WITNESS WHEREOF, the undersigned have executed this Release of Intellectual Property Security Interest as of the date first above written.

LENDER:

MIDCAP FUNDING III, LLC

By: 

Name: Robert Goodridge

Title: General Counsel

SCHEDULE A

Copyrights

| <u>Description</u> | <u>Registration/ Application Number</u> | <u>Registration/ Application Date</u> |
|--------------------|---|---|
|--------------------|---|---|

NONE

N/A

N/A

PATENTS

| <u>Title</u> | <u>Patent/Patent Application Number (Publication Number)</u> | <u>Issue/Filing Date</u> |
|--|--|--|
| Methods of treating Rett Syndrome | 12/117,586 20080280983 | 05/08/2008 |
| Dialkylamino Alkyl Esters of Pivagabine as Medicaments for the Treatment of Central Nervous System Disorders | US 7,632,836 20090111813 | 12/15/2009 |
| Polymorphic Form Of Fluoro-7-(2,2,2-Trifluoroethoxy) Phenoxathiin-10,10-Dioxide | US 7,812,050 11/773,892 20080009542 | 10/12/2010 07/05/2007 01/10/2008 |
| Oral Enteric Antidepressant Formulation | 13/143,408 20120003303 | 01/08/2010 01/05/2012 |
| Oral Sustained Release Antidepressant Formulation | 13/143,403 20120003274 | 01/08/2010 01/05/2012 |
| Pharmaceutical Compounds | 12/330,434 20090081123 | 12/08/2008 |
| Methods of treating Rett Syndrome | PCT/US2008/063129 | 11/20/2008 |
| Dialkylamino Alkyl Esters of Pivagabine as Medicaments for the Treatment of Central Nervous System Disorders | PCT/US2007/024547 | 06/05/2008 |
| Polymorphic Form Of Fluoro-7-(2,2,2-Trifluoroethoxy) Phenoxathiin-10,10-Dioxide | PCT/US2007/015533 | 01/17/2008 |
| Oral Antidepressant Formulation with Reduced Excipient Load | US 8,313,766 12/860,358 20110206769 | 11/20/2012 08/20/2010 08/25/2011 |

TRADEMARKS

| <u>Description</u> | <u>Registration/Application Number</u> | <u>Registration/Application Date</u> |
|--------------------|--|--|
| CENERX | 3,662,094 | 07/28/2009 |
| CENERX (Canada) | 1,333,088 | 01/29/2007 |
| MERIMA | 77/467,853 | 05/07/2008 |
| MYRIMA | 77/467,852 | 05/07/2008 |
| ATYRIMA | 77/467,850 | 05/07/2008 |
| TRIRIMA | 3,687,175 | 09/22/2009 |
| ATYREMA | 77/478,437 | 05/19/2008 |
| TYRIMA | 77/094,042 | 01/29/2007 |
| AYRENE | 77/807,249 | 08/18/2009 |

SCHEDULE D

Mask Works

| <u>Description</u> | <u>Registration/ Application Number</u> | <u>Registration/ Application Date</u> |
|--------------------|---|---|
| NONE | N/A | N/A |